Martine Rothblatt Sells Shares of United Therapeutics
CEO Martine Rothblatt sold 9,500 shares of United Therapeutics on June 26, 2026.
Key Points
- United Therapeutics' CEO Martine Rothblatt sold 9,500 shares on June 26, 2026, at a price of $548.11.
- The stock, trading on NasdaqGS as UTHR, has a market cap of $23.03 billion and a P/E ratio of 20.1.
- Analysts maintain a 'buy' consensus with price targets ranging from $516 to $750.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Martine Rothblatt, the Chairperson and CEO of United Therapeutics Corporation, sold 9,500 shares of the company on June 26, 2026. The sale was not part of a pre-planned trading program and took place as the stock traded at $548.11 on the NasdaqGS.
Insider Buying and Selling at United Therapeutics Corporation
On June 26, 2026, Martine Rothblatt executed multiple transactions involving United Therapeutics shares. In addition to selling 9,500 shares, Rothblatt also acquired 9,500 shares at an average price of $135.42 on the same day. This activity follows similar transactions conducted on June 25, 2026, where Rothblatt bought and sold the same number of shares under different circumstances.
United Therapeutics Corporation Stock Up 4.5%
Shares of NasdaqGS:UTHR traded near $548.11 on Tuesday. United Therapeutics has a market cap of about $23.03 billion and a P/E ratio of 20.1, with a forward P/E of 17.1. The stock's 52-week range spans from $272.12 to $609.35, and it has a 50-day moving average of $562.17 and a 200-day moving average of $501.21. The company maintains a strong current ratio of 4.79 and a quick ratio of 4.12.
$UTHR stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts have recently updated their views on United Therapeutics. On May 7, 2026, RBC Capital maintained its 'buy' rating with a price target of $701, while Wells Fargo upgraded its rating to 'buy' with a target of $738. The consensus among analysts is a 'buy' rating, with a mean target price of $665.23, based on 13 opinions.
About United Therapeutics
United Therapeutics Corporation, based in Silver Spring, Maryland, is a healthcare company specializing in the development and commercialization of treatments for chronic and life-threatening diseases. The company offers a range of products, including inhaled solutions and tablets for pulmonary arterial hypertension, as well as treatments for neuroblastoma. Founded in 1996, United Therapeutics employs around 1,400 people and is led by CEO Dr. Martine Rothblatt.
Bottom Line
Martine Rothblatt's recent sale of United Therapeutics shares highlights ongoing insider activity at the company. Investors often monitor such transactions for insights into executive confidence. United Therapeutics remains a significant player in the healthcare sector, with analysts maintaining a positive outlook on its stock. Remember, insider transactions are reported after the fact and might not reflect current holdings.
Get United Therapeutics Corporation alerts
New 13F filings, insider trades, and analyst moves on $UTHR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.